Table 1.

Details of the included RCTs

Study	Country (No. of Sites)	Year of Publication	Total Number of Patients	DES Type	Primary Endpoint	Events Rate, DES	Events Rate, BMS	P Value
RRISC	Belgium	2006	75	First‐generation SES	6‐mo angiographic in‐stent late lumen loss	0.38 ± 0.51 mm	0.79 ± 0.66 mm	0.001
BASKET	Switzerland	2009	47	First‐generation SES and PES	MACE (cardiac death, nonfatal MI, and non–MI‐related TVR)	21%	62%	0.007
SOS	United States (5)	2009	80	First‐generation PES	Binary angiographic restenosis/lesion at 12 mo	9%	51%	0.001
ISAR‐CABG	Germany (4)	2011	610	First‐generation SES and PES	Combined incidence of death, MI, and TLR at 12 mo	15%	22%	0.02
BASKET‐SAVAGE	Europe (3)*	2016	173	First‐generation PES	MACE (cardiac death, nonfatal MI, and TVR) at 12 mo	2.3%	17.9%	<0.001
DIVA	United States (25)	2017	597	First and second generation	TVF (composite of cardiac death, target‐vessel MI, and TVR) at 12 mo	17%	19%	0.67

Abbreviations, BASKET, Basel Stent Kosten Effektivitäts (Cost‐Effectiveness) Trial; BASKET‐SAVAGE, Basel Stent Kosten Effektivitäts Trial–Saphenous Venous Graft Angioplasty Using Glycoprotein IIb/IIIa Receptor Inhibitors and Drug‐Eluting Stents; BMS, bare‐metal Stent; DES, drug‐eluting stent; DIVA, Drug‐Eluting Stents vs Bare‐Metal Stents in Saphenous Vein Graft Angioplasty Trial; ISAR‐CABG, Is Drug‐Eluting Stenting Associated With Improved Results in Coronary Artery Bypass Grafts Trial; MACE, major adverse cardiac events; MI, myocardial infarction; PES, paclitaxel‐eluting stent; RCT, randomized clinical trial; RRISC, Reduction of Restenosis In Saphenous Vein Grafts With Cypher Sirolimus‐Eluting Stent Trial; SES, sirolimus‐eluting stent; SOS, Stenting of Saphenous Vein Grafts Trial; TLR, target‐lesion revascularization; TVF, target‐vessel failure; TVR, target‐vessel revascularization.

^*Places include: Switzerland (2), Germany (2), and Denmark (2).